ACC Action Center
Welcome to the ACC Action Center, bringing you the latest updates from the American College of Cardiology’s Annual Scientific Session & Expo, hosted in partnership with the World Congress of Cardiology. This collection will highlight emerging clinical data and explore the latest practice-changing advances in the field of cardiology.
1-15 of 61
Athlete-Focused CPET: Interpreting Physiology Beyond Standardized Testing
Heart MattersAthlete-Focused CPET: Interpreting Physiology Beyond Standardized Testing
Benjamin Levine, MD, FACC
Understanding CPET for Athletes: Protocols and Pitfalls
Heart MattersUnderstanding CPET for Athletes: Protocols and Pitfalls
Benjamin Levine, MD, FACC
Advances in Sports Cardiology: Updates from ACC 2026
Heart MattersAdvances in Sports Cardiology: Updates from ACC 2026
Jeffrey Hsu, MD, PhD
Hidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Heart MattersHidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Heart MattersPlasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
FAI and the Future of Cardiac Risk Stratification
Heart MattersFAI and the Future of Cardiac Risk Stratification
- advertisement
Rivaroxaban as effective as warfarin for left ventricular thrombus post-MI
ACC Action CenterRivaroxaban as effective as warfarin for left ventricular thrombus post-MI
Anna Bortnick, MD, PhD
Anna Bortnick, MD, PhD
Mobile integrated health program in patients with HF
ACC Action CenterMobile integrated health program in patients with HF
Ruth Masterson Creber, PhD
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC Action CenterPhase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Darren K. McGuire, MD
AI model may accelerate risk stratification of coronary revascularization in ED
ACC Action CenterAI model may accelerate risk stratification of coronary revascularization in ED
Wayne Batchelor, MD
Dapagliflozin reduces worsening HF in elderly TAVI patients
ACC Action CenterDapagliflozin reduces worsening HF in elderly TAVI patients
Wayne Batchelor, MD
- advertisement
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
ACC Action CenterLorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
Gina Lundberg, MD
Gina Lundberg, MD
Fluid restriction may not be needed in chronic HF
ACC Action CenterFluid restriction may not be needed in chronic HF
Roland Kimmenade, MD, PhD